MX2022012923A - Inhibidores de trpc6 para tratar afecciones respiratorias. - Google Patents

Inhibidores de trpc6 para tratar afecciones respiratorias.

Info

Publication number
MX2022012923A
MX2022012923A MX2022012923A MX2022012923A MX2022012923A MX 2022012923 A MX2022012923 A MX 2022012923A MX 2022012923 A MX2022012923 A MX 2022012923A MX 2022012923 A MX2022012923 A MX 2022012923A MX 2022012923 A MX2022012923 A MX 2022012923A
Authority
MX
Mexico
Prior art keywords
sup
trpc6
inhibitors
treating respiratory
respiratory conditions
Prior art date
Application number
MX2022012923A
Other languages
English (en)
Inventor
Thierry Bouyssou
Nima Soleymanlou
Paul Nicklin
Abhya Gupta
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of MX2022012923A publication Critical patent/MX2022012923A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/46—8-Azabicyclo [3.2.1] octane; Derivatives thereof, e.g. atropine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/501—Pyridazines; Hydrogenated pyridazines not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5386—1,4-Oxazines, e.g. morpholine spiro-condensed or forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Emergency Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pyridine Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)

Abstract

La invención se refiere a métodos para tratar un trastorno asociado con hiperpermeabilidad vascular y/o afecciones que surgen de la misma, que comprenden administrar a un paciente que lo necesite una cantidad farmacéuticamente efectiva de un inhibidor de TRPC6 de la Fórmula (I), (ver Fórmula) o sales farmacéuticamente aceptable de los mismos, en donde R1 a R7, A, Y y L son como se definen en la presente.
MX2022012923A 2020-04-16 2021-04-14 Inhibidores de trpc6 para tratar afecciones respiratorias. MX2022012923A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP20169943 2020-04-16
EP20203583 2020-10-23
PCT/EP2021/059683 WO2021209510A1 (en) 2020-04-16 2021-04-14 Inhibitors of trpc6 for treating respiratory conditions

Publications (1)

Publication Number Publication Date
MX2022012923A true MX2022012923A (es) 2022-11-16

Family

ID=75426626

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2022012923A MX2022012923A (es) 2020-04-16 2021-04-14 Inhibidores de trpc6 para tratar afecciones respiratorias.

Country Status (9)

Country Link
US (1) US20230149393A1 (es)
EP (1) EP4135696A1 (es)
JP (1) JP7502462B2 (es)
KR (1) KR20230004650A (es)
CN (1) CN115379841A (es)
AU (1) AU2021256963A1 (es)
CA (1) CA3173616A1 (es)
MX (1) MX2022012923A (es)
WO (1) WO2021209510A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2019158572A1 (en) * 2018-02-15 2019-08-22 Boehringer Ingelheim International Gmbh Inhibitors of trpc6
CN118055765A (zh) * 2021-10-15 2024-05-17 勃林格殷格翰国际有限公司 用于治疗脓毒症的trpc6抑制性化合物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG10202011632RA (en) 2017-10-27 2021-01-28 Boehringer Ingelheim Int Pyridine carbonyl derivatives and therapeutic uses thereof as trpc6 inhibitors
WO2019161010A1 (en) 2018-02-16 2019-08-22 Boehringer Ingelheim International Gmbh Inhibitors of trpc6
CN113677673B (zh) * 2019-04-12 2024-03-05 勃林格殷格翰国际有限公司 Trpc6的抑制剂

Also Published As

Publication number Publication date
CA3173616A1 (en) 2021-10-21
KR20230004650A (ko) 2023-01-06
JP2023520917A (ja) 2023-05-22
CN115379841A (zh) 2022-11-22
AU2021256963A1 (en) 2022-09-15
WO2021209510A1 (en) 2021-10-21
JP7502462B2 (ja) 2024-06-18
EP4135696A1 (en) 2023-02-22
US20230149393A1 (en) 2023-05-18

Similar Documents

Publication Publication Date Title
CR20210563A (es) Compuestos y métodos para el tratamiento de covid-19
MY196455A (en) Nitrile-Containing Compounds Useful as Antiviral Agents for The Treatment of a Coronavirus Infection
MX2023000798A (es) Peptidos funcionalizados como agentes antivirales.
MX2023005984A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
CR20230310A (es) Inhibidores de prmt5
ZA202307575B (en) Methods and modified nucleosides for treating coronavirus infections
MX2021007970A (es) Derivado de 6-oxo-1,6-dihidropiridazina, metodo de preparacion del mismo y uso medico del mismo.
MX2023005983A (es) Nuevos agentes antivirales derivados de la espiropirrolidina.
MX2022010011A (es) Inhibidores de prmt5 novedosos.
MX2023001756A (es) Peptidos funcionalizados como agentes antivirales.
MX2010009739A (es) Inhibidores de cinasa pim y metodos para su uso.
MX2022012923A (es) Inhibidores de trpc6 para tratar afecciones respiratorias.
MX2022011804A (es) Uso de agentes para el tratamiento de condiciones respiratorias.
WO2021168483A3 (en) Treatment of human coronavirus infections using alpha-glucosidase glycoprotein processing inhibitors
MX2022013647A (es) Imidazopiridazinas como moduladores de il-17.
MX2023009222A (es) Inhibidores tricíclicos-amido-bicíclicos de prmt5.
MX2022009197A (es) Metodos de tratamiento para deficiencia de alfa-1 antitripsina.
UY31417A1 (es) Una composicion farmacéutica y un proceso para dicha composicion farmacéutica
MX2022009967A (es) Compuestos para el tratamiento de la infeccion por coronavirus.
MX2023003332A (es) Inhibidores del elemento 1 interdispersado largo (line-1) para el tratamiento de enfermedades.
MX2022003845A (es) Tratamientos cognitivos medicinales.
WO2019139956A3 (en) Prevention and treatment of organ fibrosis
MX2020007817A (es) Prevención y tratamiento del trastorno del sueño.
MX2023005303A (es) Inhibidor de raf para el tratamiento del glioma de bajo grado.
MX2022004806A (es) Metodos y composiciones para tratar la anemia drepanocitica con un inhibidor de la ferroportina (vit-2763).